Abstract
Nebulization simplifies the administration of effective inhaled medications to young asthmatics who experience hand-to-lung co-ordination problems and inspiratory difficulties associated with metered-dose and drypowder inhalers, respectively.The objective of this double-blind, double-dummy, multicentre, randomized, parallel-group study was to compare the efficacy and safety of cot-ticosteroids given by nebulization or metered-dose inhalation in paediatric patients with exacerbation of asthma. Following a 24-h run-in period, I5 I patients, aged 6-I6 years, with moderate to severe exacerbation of asthma were randomized to one of two treatment groups for 4weeks: beclometasone dipropionate (BDP) suspension for nebulization I600 pgda)r' b.i.d. given via a nebulizer (n=75), or BDP spray 800pgday-1 b.i.d. given via a metered-dose inhaler (MDI) plus spacer (BDP MDI) (n=76). Superimposable and statistically significant improvements over baseline were noted at study end for the two treatment groups in the various efficacy parameters evaluated (pulmonary function tests, asthma symptoms scores, and the use of rescue salbutamol).The primary efficacy endpoint was the morning pulmonary expiratory flow rate (PEFR). In the BDP nebulization group, mean morning PEFR increased statistically significantly from 233.2 f 86.3 I min-I to 322.0 & IO I .8 I rninp', while in the BDP MDI group the increase was from 222.9 * 87.3 I min-' to 3 14.9 + 96.6 I minm 1. Moreover, an additional 4-week treatment period at half doses, completed by 26 patients, demonstrated that improvements were maintained or further enhanced. The two treatments were equally well tolerated. A total of 25 and 26 patients in the BDP nebulization and BDP MDI groups, respectively, reported adverse events during the treatment period, and these were generally mild. In conclusion, the results of this tiudy demonstrate that BDP suspension for nebulization I600 pg day-1 given via a nebulizer and BDP spray 800 pg day-' given via an MDI plus spacer are equally effective, with an acceptable safety and tolerability profile, when used in paediatric patients with moderate to severe asthma exacerbation. and BDP MDI groups at the end of the initial 4-week treatment period. In the BDP nebulization group, mean values increased from 233.2 I min-1 to 322.0 I mini, while in the BDP MDI group the increase was from 222.9 I min-1 to 3 14.9 I mini ( Figure I ). The lower limit of the unilateral 95% confidence interval was -2 I .7 and did not exceed -IO% (-32.0 In the BDP nebulization group, evening PEFR improved statistically significantly from a mean of 24 I .7 I min-1 at baseline to 330.8 I min-I after 4 weeks' treatment, and in the BDP MDI group from 237.1 I min-1 to 323.0 I min-I, with no significant difference noted between the two treatments ( Figure 2 ). For the additional 4-week period of treatment, mean values increased progressively in the two groups from week 4 to week 8: from 354.9 I min-r to 37 I .O I mini in the BDP nebulization group, and from 303.3 I min-1 to 3 18.4 I min-1 in the BDP MDI group (Figure 2) .
INTRODUCTION
Mean FEV, rose statistically significantly in the BDP nebulization group from I .4 litres at day I to 2.0 litres at treatment end, and in the BDP MDI group from I .5 to 2. I litres, with no significant between-group difference noted (Figure 2) . Mean values increased again for both groups in the additional 4-week period of treatment: from 2.2 litres at week 4 to 2.3 litres at week 8 in the BDP nebulization group, and from 2. I to 2.3 litres in the BDP MDI group (Figure 2) .
In the BDP nebulization group, mean FVC increased statistically significantly from I.8 litres at day I to 2.3 litres after 4 weeks' treatment, and in the BDP MDI group from I .8 to 2.4 litres, with no significant difference found between the two treatments ( Figure 2 ). In the additional 4-week treatment period, further increases in mean values were reported: from 2.6 litres at week 4 to 2.7 litres at week 8 and from 2.6 to 2.8 litres in the BDP nebulization and BDP MDI groups, respectively (Figure 2 ).
Evaluation of efficacy:
Signs and symptoms and rescue medication Following treatment for 4 weeks, superimposable and statistically significant improvements in morning and evening asthma symptoms scores were reported for the two treatment arms. Mean values fell in both groups from I.8 at baseline to 0.4 at treatment end for morning scores, and from I *9 to O-4 in the BDP nebulization group and I .9 to 0.5 in the BDP MDI group in evening scores. Moreover, in the additional 4-week treatment period improvements were maintained or further enhanced in both groups, with mean morning scores falling from 0.6 at week 4 to 0.4 at week 8 in the BDP nebulization group, and from I.0 to 0.7 in the BDP MDI group, and mean evening scores from 0.6 to 0.4 in the BDP nebulization group, and from I.0 to 0.9 in the BDP MDI group.
Equivalent statistically significant reductions were also reported in morning and evening salbutamol consumption in both groups at the end of the 4-week treatment period when compared with baseline. For morning consumption, the mean number of puffs fell from O-8 puffs day-r to 0.3 puffs day-l in the BDP nebulization group, and from 0.9 puffs day-to 0.2 puffs dayi in the BDP MDI group, and for evening consumption from 2.1 puffs day' to 0.5 puffs day' in the BDP nebulization group, and from I .9 puffs dayi to 0.6 puffs day-r in the BDP MDI group. Values remained stable or further declined for the additional 4-week treatment period: changes from O-5 puffs day' at week 4 to 0.3 puffs day' at week 8 were noted for the BDP nebulization group, and from O-3 puffs day' to 0.2 puffs day' in the BDP MDI group, for morning use; and from I. I puffs day-r to 0.7 puffs day-r in the BDP nebulization group, and from I .O puffs day-r to I .I puffs day-r in the BDP MDI group, for evening use. and by a similar extent with the two delivery systems. In addition, the safety profile was comparable for the two groups with respect to the incidence of adverse events, potential adrenal suppression (as indicated by morning serum cortisol levels), and vital signs.
In conclusion, this study demonstrates that BDP suspension for nebulization 1600 ug day-1 given via a nebulizer and BDP spray 800 ,ug day-' given via an MDI plus spacer are effective and therapeutically equivalent, with a good safety and tolerability profile, when used as a treatment for asthma exacerbation in school-age children.
